82 related articles for article (PubMed ID: 7025036)
1. Antitoxic immunity in cholera and enterotoxigenic Escherichia coli (ETEC) diarrhea.
DuPont HL; Evans DG; Evans DJ; Satterwhite TK
Pharmacol Ther; 1981; 13(2):249-55. PubMed ID: 7025036
[No Abstract] [Full Text] [Related]
2. Enterotoxigenic Escherichia coli diarrhea in an endemic area prepares the intestine for an anamnestic immunoglobulin A antitoxin response to oral cholera B subunit vaccination.
Holmgren J; Svennerholm AM; Gothefors L; Jertborn M; Stoll B
Infect Immun; 1988 Jan; 56(1):230-3. PubMed ID: 3275584
[TBL] [Abstract][Full Text] [Related]
3. Vaccine development for the control of cholera and related toxin-induced diarrhoeal diseases.
Holmgren J; Svennerholm AM
Ciba Found Symp; 1985; 112():242-70. PubMed ID: 3891255
[TBL] [Abstract][Full Text] [Related]
4. Development of a vaccine against experimental cholera and Escherichia coli diarrheal disease.
Rappaport RS; Bonde G
Infect Immun; 1981 May; 32(2):534-41. PubMed ID: 7019073
[TBL] [Abstract][Full Text] [Related]
5. [Protection against enterotoxigenic Escherichia coli infections].
Steinsland H; Valentiner-Branth P; Gjessing HK; Aaby P; Sommerfelt H; Mølbak K
Ugeskr Laeger; 2004 Nov; 166(45):4051-3. PubMed ID: 15565966
[No Abstract] [Full Text] [Related]
6. Protection from natural infections with enterotoxigenic Escherichia coli: longitudinal study.
Steinsland H; Valentiner-Branth P; Gjessing HK; Aaby P; Mølbak K; Sommerfelt H
Lancet; 2003 Jul; 362(9380):286-91. PubMed ID: 12892959
[TBL] [Abstract][Full Text] [Related]
7. Analysis of efficacy of CVD 103-HgR live oral cholera vaccine against all-cause travellers' diarrhoea in a randomised, double-blind, placebo-controlled study.
Leyten EM; Soonawala D; Schultsz C; Herzog C; Ligthelm RJ; Wijnands S; Visser LG
Vaccine; 2005 Oct; 23(43):5120-6. PubMed ID: 15982790
[TBL] [Abstract][Full Text] [Related]
8. Review on pathogenicity mechanism of enterotoxigenic Escherichia coli and vaccines against it.
Mirhoseini A; Amani J; Nazarian S
Microb Pathog; 2018 Apr; 117():162-169. PubMed ID: 29474827
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of whole-blood gamma interferon response to the Vibrio cholerae toxin B subunit and resistance to enterotoxigenic Escherichia coli-associated diarrhea.
Flores J; DuPont HL; Paredes-Paredes M; Aguirre-Garcia MM; Rojas A; Gonzalez A; Okhuysen PC
Clin Vaccine Immunol; 2010 May; 17(5):879-81. PubMed ID: 20219880
[TBL] [Abstract][Full Text] [Related]
10. Assessing antigen specific HLA-DR+ antibody secreting cell (DR+ASC) responses in whole blood in enteric infections using an ELISPOT technique.
Bhuiyan TR; Hoq MR; Nishat NS; Al Mahbuba D; Rashu R; Islam K; Hossain L; Harris JB; Ryan ET; Calderwood SB; Svennerholm AM; Qadri F
Microbes Infect; 2018 Feb; 20(2):122-129. PubMed ID: 29104143
[TBL] [Abstract][Full Text] [Related]
11. The discovery of cholera - like enterotoxins produced by Escherichia coli causing secretory diarrhoea in humans.
Sack RB
Indian J Med Res; 2011 Feb; 133(2):171-80. PubMed ID: 21415491
[TBL] [Abstract][Full Text] [Related]
12. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
Roland KL; Cloninger C; Kochi SK; Thomas LJ; Tinge SA; Rouskey C; Killeen KP
Vaccine; 2007 Dec; 25(51):8574-84. PubMed ID: 18045752
[TBL] [Abstract][Full Text] [Related]
13. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea.
Sánchez J; Holmgren J
Curr Opin Immunol; 2005 Aug; 17(4):388-98. PubMed ID: 15963708
[TBL] [Abstract][Full Text] [Related]
14. Avirulent K88 (F4)+ Escherichia coli strains constructed to express modified enterotoxins protect young piglets from challenge with a virulent enterotoxigenic Escherichia coli strain that expresses the same adhesion and enterotoxins.
Santiago-Mateo K; Zhao M; Lin J; Zhang W; Francis DH
Vet Microbiol; 2012 Oct; 159(3-4):337-42. PubMed ID: 22541162
[TBL] [Abstract][Full Text] [Related]
15. Intestinal immunoglobulin a response to naturally acquired enterotoxigenic Escherichia coli in US travelers to an endemic area of Mexico.
Estrada-García MT; Jiang ZD; Adachi J; Mathewson JJ; DuPont HL
J Travel Med; 2002; 9(5):247-50. PubMed ID: 12962598
[TBL] [Abstract][Full Text] [Related]
16. Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans.
Zhang W; Sack DA
Expert Rev Vaccines; 2012 Jun; 11(6):677-94. PubMed ID: 22873126
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiological effects of Vibrio cholerae and enterotoxigenic Escherichia coli and their exotoxins on eucaryotic cells.
Richards KL; Douglas SD
Microbiol Rev; 1978 Sep; 42(3):592-613. PubMed ID: 82199
[No Abstract] [Full Text] [Related]
18. New vaccines against bacterial toxins.
Rappuoli R; Pizza M; Douce G; Dougan G
Adv Exp Med Biol; 1996; 397():55-60. PubMed ID: 8718582
[No Abstract] [Full Text] [Related]
19. Mouse intestinal innate immune responses altered by enterotoxigenic Escherichia coli (ETEC) infection.
Ren W; Yin J; Duan J; Liu G; Zhu X; Chen S; Li T; Wang S; Tang Y; Hardwidge PR
Microbes Infect; 2014 Nov; 16(11):954-61. PubMed ID: 25267358
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with Dukoral against travelers' diarrhea (ETEC) and cholera.
Jelinek T; Kollaritsch H
Expert Rev Vaccines; 2008 Jul; 7(5):561-7. PubMed ID: 18564011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
